Oral Drug Delivery Videos

31. Patient Safety Through Overdose Protection With Elysium Therapeutics' Greg Sturmer 11/18/2024

    Drug overdoses can result both from knowingly risky behavior, such as opioid use disorder, and from unwitting patient acts of over-consumption. In this episode of Sit and Deliver, Greg Sturmer, co-founder and CEO of biopharmaceutical company Elysium Therapeutics, talks with Sit and Deliver host Tom von Gunden about ways to add overdose inhibitors to oral medications prone to abuse or misuse.

32. Defying Dysphagia Via Gel-Based Delivery With Gelteq's Nathan Givoni 1/6/2025

    Patients suffering from dysphagia, or difficulty swallowing, have historically faced limited options for how they receive medications and what kinds can be effectively delivered to them. In this episode of Sit and Deliver, host Tom von Gunden speaks with Gelteq CEO Nathan Givoni about advances in gel-based oral delivery that would allow patients to overcome the challenges dysphagia presents. 

33. Next Generation Drug And Biologics Delivery Technologies 5/23/2025

    In this segment of the Drug Delivery Leader Live online event, Innovations In Drug Delivery: Opportunities For Enhancing Familiar, Mature Approaches, host Fran DeGrazio asks panelists James Wabby of biopharmaceutical company AbbVie and Carolyn Dorgan and Courtney Evans of device consultancy Suttons Creek to comment on trends and advances they anticipate in the next phase of delivery development. Those include combination therapies, nanotechnology, reconstitution, and microfluidics.

34. Diffucaps Technology 8/29/2024

    Discover how Diffucaps technology offers precise drug release, tailored dosage, and enhanced solubility, while minimizing irritation.

35. Rapid Development Of Amorphous Solid Dispersions For Bioavailability

    See how an amorphous solid dispersion (ASD) of acalabrutinib was designed using in vitro studies and in silico modeling. Understand how ASD formulations can enhance bioavailability.

36. Improve The Bioavailability Of Poorly Soluble Drugs 3/19/2024

    KinetiSol is a fusion-based, solvent-free process that utilizes frictional and shear energies — in a fraction of the time of other amorphous solid dispersion technologies.

37. What Happened to CAPA (Corrective and Preventive Actions) Requirements? 7/11/2024

    Is CAPA still part of the requirements picture for the new QMSR? In this segment of the Drug Delivery Leader Live event New FDA QMSR: Its Role in Part 4 Compliance for Combination Products, consultant Ed Bills of Edwin Bills Consultant discusses changes in the treatment of corrective and preventive actions.

38. Increase Spray Drying Throughput For Brick Dust Compounds

    We discuss three enabling technologies designed to improve drug solubility in organic solvents for spray drying and define the advantages and risks of each technology.

39. Solvent-Free, Fusion-Based Amorphic Dispersion Process 7/11/2024

    Discover a solvent-free, fusion-based process that leverages frictional and shear forces to rapidly convert crystalline drugs and polymers into amorphous solid dispersions (ASDs).

40. Achieving Desired Particle Size And Yield Through Efficient Micronization 1/22/2025

    In this webinar, experts examine how the right combination of advanced technology and specialized expertise can leverage micronization to address the challenges often faced by small molecule drugs.